Sec Form 4 Filing - Sero Capital LLC @ AUDIOEYE INC - 2019-08-14

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Sero Capital LLC 2. Issuer Name and Ticker or Trading Symbol AUDIOEYE INC [ AEYE] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 119 WASHINGTON AVE., SUITE 403 3. Date of Earliest Transaction (MM/DD/YY) 08/14/2019 (Street) MIAMI BEACH, FL33139 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/14/2019 X( 4 ) 590,000 A $ 1.63 ( 1 ) ( 2 ) 2,246,740 I Through Sero Capital LLC ( 3 ) Common Stock 08/14/2019 X( 4 ) 295,000 A $ 1.63 ( 1 ) ( 2 ) 2,541,740 I Through Sero Capital LLC ( 3 ) Common Stock 08/14/2019 X( 4 ) 42,858 A $ 4.07 ( 1 ) ( 2 ) 2,584,598 I Through Sero Capital LLC ( 3 ) Common Stock 155,169 D ( 5 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Se curity (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrant (right to buy) $ 2.5 08/14/2019 J( 1 )( 2 ) 590,000 11/06/2015 11/06/2020 Common Stock 590,000 ( 1 ) ( 2 ) 0 I Through Sero Capital LLC ( 3 ) Warrant (right to buy) $ 1.63 ( 1 ) ( 2 ) 08/14/2019 J( 1 )( 2 ) 590,000 11/14/2019 11/06/2020 Common Stock 590,000 ( 1 ) ( 2 ) 590,000 I Through Sero Capital LLC ( 3 ) Warrant (right to buy) $ 2.5 08/14/2019 J( 1 )( 2 ) 295,000 11/17/2017 11/17/2022 Common Stock 295,000 ( 1 ) ( 2 ) 0 I Through Sero Capital LLC ( 3 ) Warrant (right to buy) $ 1.63 ( 1 ) ( 2 ) 08/14/2019 J( 1 )( 2 ) 295,000 11/14/2019 11/17/2022 Common Stock 295,000 ( 1 ) ( 2 ) 295,000 I Through Sero Capital LLC ( 3 ) Warrant (right to buy) $ 6.25 08/14/2019 J( 1 )( 2 ) 42,858 08/23/2018 09/29/2022 Common Stock 42,858 ( 1 ) ( 2 ) 0 I Through Sero Capital LLC ( 3 ) Warrant (right to buy) $ 4.07 ( 1 ) ( 2 ) 08/14/2019 J( 1 )( 2 ) 42,858 11/14/2019 09/29/2022 Common Stock 42,858 ( 1 ) ( 2 ) 42,858 I Through Sero Capital LLC ( 3 ) Warrant (right to buy) $ 1.63 ( 1 ) ( 2 ) 08/14/2019 X( 4 ) 590,000 11/14/2019 11/06/2020 Common Stock 590,000 $ 0 0 I Through Sero Capital LLC ( 3 ) Warrant (right to buy) $ 1.63 ( 1 ) ( 2 ) 08/14/2019 X( 4 ) 295,000 11/14/2019 11/17/2022 Common Stock 295,000 $ 0 0 I Through Sero Capital LLC ( 3 ) Warrant (right to buy) $ 4.07 ( 1 ) ( 2 ) 08/14/2019 X( 4 ) 42,858 11/14/2019 09/29/2022 Common Stock 42,858 $ 0 0 I Through Sero Capital LLC ( 3 ) Warrant (right to buy) $ 6 08/14/2019 P( 6 )( 7 ) 146,667 11/14/2019 08/14/2020 Common Stock 146,667 ( 6 ) ( 7 ) 146,667 I Through Sero Capital LLC ( 3 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Sero Capital LLC 119 WASHINGTON AVE., SUITE 403 MIAMI BEACH, FL33139 X Moradi David 119 WASHINGTON AVE, SUITE 403 MIAMI BEACH, FL33139 X Signatures SERO CAPITAL LLC, Name: /s/ David Moradi, Title: Managing Partner 08/16/2019 Signature of Reporting Person Date /s/ David Moradi 08/16/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On August 14, 2019, Sero Capital LLC ("Sero Capital") entered into Omnibus Amendments to Common Stock Warrants (the "Amendments") with AudioEye, Inc. (the "Issuer") pursuant to which the exercise prices for several warrants to purchase common stock of the Issuer held by Sero Capital were adjusted. Pursuant to the Amendments, the exercise price for warrants to purchase 590,000 shares of the Issuer's common stock with an expiration date of November 6, 2020 was adjusted to a price of $1.63 per share, if the warrants were exercised on or before August 16, 2019, provided the warrants were exercised in full and the exercise price would be paid in cash, or $2.50, if the warrants were exercised after August 16, 2019. ( 2 )(continued from footnote 1) In addition, pursuant to the Amendments, the exercise price of warrants to purchase 295,000 shares of the Issuer's common stock with an expiration date of November 17, 2022 was adjusted to a price of $1.63 per share, if the warrants were exercised on or before August 16, 2019, provided the warrants were exercised in full and the exercise price would be paid in cash, or $2.50, if the warrants were exercised after August 16, 2019. Further, pursuant to the Amendments, the exercise price of warrants to purchase 42,858 shares of the Issuer's common stock with an expiration date of September 29, 2022 was adjusted to a price of $4.07 per share, if the warrants were exercised on or before August 16, 2019, provided the warrants were exercised in full and the exercise price would be paid in cash, or $6.25, if the warrants were exercised after August 16, 2019. ( 3 )Securities of the Issuer held directly by Sero Capital. David Moradi is the Managing Partner of Sero Capital and may be deemed to direct all voting and investment decisions made by Sero Capital. ( 4 )On August 14, 2019, Sero Capital exercised in full all of the warrants the exercise prices of which were adjusted pursuant to the Amendments. ( 5 )Securities of the Issuer held directly by David Moradi. ( 6 )On August 14, 2019, Sero Capital entered into a Loan Agreement (the "Loan Agreement") with the Issuer pursuant to which Sero Capital agreed to make advances to the Issuer in an amount up to $2,000,000 in the aggregate during a one-year term at an interest rate of 10% per annum. Interest payments on advances made under the Loan Agreement may be paid by the Issuer in either cash or in Issuer common stock, at the Issuer's option. In the event that the Issuer shall elect to make a payment of interest in the form of Issuer common stock, the number of shares issued by the Issuer with respect to each payment of interest shall be equal to the dollar amount of the applicable interest payment divided by the lesser of (x) $6.07, or (y) the volume weighted average trading price of the common stock for the five trading days immediately preceding the interest payment date. ( 7 )(continued from footnote 6) As consideration for entering into the Loan Agreement, on August 14, 2019, the Issuer issued to Sero Capital warrants to purchase 146,667 shares of Issuer common stock at an exercise price of $6.00 per share. Such warrants may be exercised for cash or on a cashless basis, provided that if the fair market value on the expiration date exceeds the exercise price on the expiration date, then the warrants will be deemed to have been exercised in full (to the extent not previously exercised) on a cashless basis on the expiration date. The number of shares purchasable upon the exercise of the warrants and the exercise price are subject to certain antidilution adjustments described in the warrants.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.